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Abstract
Wolcott-Rallison syndrome (WRS) is a rare autosomal recessive disease, characterized by neonatal/early-onset non-
autoimmune insulin-requiring diabetes associated with skeletal dysplasia and growth retardation. Fewer than 60 cases
have been described in the literature, although WRS is now recognised as the most frequent cause of neonatal/early-
onset diabetes in patients with consanguineous parents. Typically, diabetes occurs before six months of age, and skele-
tal dysplasia is diagnosed within the first year or two of life. Other manifestations vary between patients in their nature
and severity and include frequent episodes of acute liver failure, renal dysfunction, exocrine pancreas insufficiency, intel-
lectual deficit, hypothyroidism, neutropenia and recurrent infections. Bone fractures may be frequent. WRS is caused by
mutations in the gene encoding eukaryotic translation initiation factor 2a kinase 3 (EIF2AK3), also known as PKR-like
endoplasmic reticulum kinase (PERK). PERK is an endoplasmic reticulum (ER) transmembrane protein, which plays a key
role in translation control during the unfolded protein response. ER dysfunction is central to the disease processes. The
disease variability appears to be independent of the nature of the EIF2AK3 mutations, with the possible exception of an
older age at onset; other factors may include other genes, exposure to environmental factors and disease management.
WRS should be suspected in any infant who presents with permanent neonatal diabetes associated with skeletal dys-
plasia and/or episodes of acute liver failure. Molecular genetic testing confirms the diagnosis. Early diagnosis is recom-
mended, in order to ensure rapid intervention for episodes of hepatic failure, which is the most life threatening
complication. WRS should be differentiated from other forms of neonatal/early-onset insulin-dependent diabetes based
on clinical presentation and genetic testing. Genetic counselling and antenatal diagnosis is recommended for parents
of a WRS patient with confirmed EIF2AK3 mutation. Close therapeutic monitoring of diabetes and treatment with an
insulin pump are recommended because of the risk of acute episodes of hypoglycaemia and ketoacidosis. Interventions
under general anaesthesia increase the risk of acute aggravation, because of the toxicity of anaesthetics, and should be
avoided. Prognosis is poor and most patients die at a young age. Intervention strategies targeting ER dysfunction pro-
vide hope for future therapy and prevention.
Disease name and synonyms
Wolcott-Rallison syndrome (WRS) was named after
Drs Wolcott and Rallison, who first described this syn-
drome in three affected siblings [1]. It is also known as
multiple epiphyseal dysplasia and early-onset diabetes
mellitus, according to the main clinical manifestations
recognized initially.
Definition and diagnostic criteria
WRS is characterized by insulin-requiring diabetes that
generally appears during the neonatal period or in the
first six months of life, with a frequently acute presenta-
tion of severe diabetic ketoacidosis at disease onset [2-4].
Two patients with a later onset have been reported, at 14
months [4] and 30 months [2]. Hyperglycemia is initially
the only manifestation of the disease, the rest of the bio-
logical assessment being normal. Anti-islet cell (ICA),
anti-insulin, anti-glutamic acid decarboxylase (GAD) and
anti-tyrosine phosphatase (IA2) antibodies are negative.
With time, short stature and skeletal dysplasia with
radiographic abnormalities progressively develop and are
generally diagnosed after diabetes onset, although early
signs, including delayed or difficult walking, osteoporosis,
deficient mineralization or mild bone abnormalities may
be present on close examination and radiography as early
as the onset of diabetes. Additional clinical features,
which vary between patients, are usually diagnosed after
diabetes onset.
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Epidemiology
This is a rare disease, with fewer than 60 cases
described in the literature [3,4]. In the large majority of
cases, affected individuals are from populations in which
consanguineous marriages are frequent, such as the
Middle-East, North Africa, Pakistan and Turkey. Despite
its recognition as a very rare disease, with very few cases
reported in the literature before the first genetic study
leading to gene identification, WRS now appears as the
most frequent cause of Permanent Neonatal Diabetes
Mellitus (PNDM) in consanguineous families ([4] and C.
Julier, unpublished data). It is likely that the syndrome
was rarely diagnosed before the identification of the
responsible gene, and may still be underdiagnosed, as
patients may die before expressing the minimum clinical
features of neonatal/early-onset diabetes and epiphyseal
dysplasia or because the association may not be recog-
nized in younger patients.
Clinical characteristics
The two main clinical features are well described in the
first publication of Wolcott and Rallison [1], and are
represented by neonatal/early-onset diabetes and multi-
ple epiphyseal dysplasia. Hepatic dysfunction, manifest-
ing in the form of elevated hepatic enzymes, liver
enlargement and recurrent acute liver failure, is the
third most frequently observed manifestation, and now
appears as a characteristic feature of this syndrome.
This review is based on the clinical characteristics of
patients in our own experience and on the description
of cases reported in the literature, as well as two recent
compilations of large series of WRS patients: a descrip-
tion of new cases and literature review of 38 patients
from 23 families [3] and a recent study of 29 WRS
patients from 25 families [4].
Diabetes
In the vast majority of cases the onset is observed dur-
ing the first months of life (extreme ages at onset
between 1 day and 30 months). In all but two of the
cases reported to date diabetes onset was before the age
of 6 months. Diabetes is an obligate feature of WRS, by
definition, and it is permanent and totally insulin-depen-
dent from the onset. Although birth weight is generally
within normal range, there is now evidence for slightly
reduced birth weight in WRS patients (median: -1.4 SD)
[4]. The origin of diabetes in WRS is not autoimmune
as evidenced by the absence of antibodies specific for
type 1 diabetes.
Bone dysplasia
WRS is characterized by multiple epiphyseo-metaphyseal
dysplasia whose major features affect the long bones,
pelvis and vertebrae, while the skull is usually normal.
Dysplastic changes on knee radiographs are illustrated
by enlarged and irregular metaphyses with prominent
beaks. Femoral and tibial epiphyses are flattened. On the
hand, the carpal bones and phalanges show tubulation
defects and appear short and enlarged. The carpal cen-
tres are small and irregular, the proximal phalanges
show especially dense and cone-shaped epiphyses
(Figure 1A) [5]. Interestingly, bone mineralization is
affected, as was noted in the early descriptions of the
syndrome [6]. Osteopenia is associated with thin cor-
tices and poorly calcified epiphyses which are undeve-
loped. Multiple and frequent fractures can be observed.
Blood calcium and phosphorus values are normal. At
the spine, the characteristics correspond to those of
mild platyspondyly. Vertebrae show irregular upper and
lower plates with frequent ossification defects at the
anterior edge (Figure 1B). Changes are especially marked
at the dorso-lumbar level with a consequent appearance
of thoracic kyphosis and/or lumbar lordosis. Clinically,
the chest is rather broad and flattened in the antero-
posterior direction (dwarfism with short trunk) (Figure
2A). At the pelvic level, the radiographs usually show
abnormal iliac wings and dysplastic acetabular roofs
(Figure 1C). Dislocation or subluxation of the femoral
heads is a common complication. Femoral epiphyses are
flattened with coxa vara. Clinically, difficulty in walking
or running is frequent, with a “duck-like” gait related to
stiff hips and limited abduction. In some cases, the
extreme skeletal condition may manifest with severe
cervical spine instability, which may result in spinal cord
compression and motor neuropathy in arms and legs
(T. Barrett, pers. communication).
Hepatic dysfunction
Hepatic disease appears to be a characteristic feature of
WRS patients. The liver impairment is typically repre-
sented by recurrent acute episodes of cytolysis, with or
without cholestasis, and even by episodes of liver failure
and the possibility of chronic liver dysfunction in older
patients. Typically, these episodes are recurrent with
spontaneous remission, and their severity is variable.
These events are accompanied by an increase in liver
volume, which is documented clinically or on ultra-
sound, with elevated liver enzymes and/or elevated bilir-
ubin levels. They may regress spontaneously or they
may be particularly severe, associated with multiorgan
failure, and may result in death. These episodes are
often triggered by intercurrent diseases such as mild
infections of upper airways, and may be complicated by
jaundice, hypoglycemia, and even by coma with
impaired consciousness in severe cases. Recovery from
these events may result in an aggravation of the general
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condition of patients [7]. Generally, WRS patients have a
tendency for recurrent hypoglycemic episodes, most
likely as a consequence of liver dysfunction, with
impaired gluconeogenesis [8].
Other clinical features
Other clinical characteristics have been described but
are inconsistently present and/or reported. Episodes of
impaired renal function, or self-limiting renal insuffi-
ciency, are described as occurring concomitantly with
hepatic manifestations. Global dysfunction of pancreas is
rather rare. In some cases, hypotrophy of pancreas has
been documented by ultrasound, computed tomography
(CT) or magnetic resonance imagining (MRI) [9,10], and
evidence of exocrine pancreatic insufficiency was
reported in 8 out of 30 patients in the series of Ozbek
et al., four of whom were homozygous for the same
mutation [3]. In the series of patients studied by Rubio-
Cebezas et al., 2 out of 29 patients required pancreatic
enzyme treatment [4]. In terms of neuro-psychological
Figure 1 Radiographs of a WRS patient (age 13 years). A. Hand: the carpal bones are small and irregular with dysplastic distal radial and
ulnar epiphyses; several phalanges are dysplastic with abnormal metaphyseal cupping at the proximal ends. B. Spine: dorsal region of spine
shows flattening of the vertebral bodies with defects at the anterior edges. C. Pelvis: the acetabular roofs are hypoplastic with dysplastic capital
femoral epiphyses.
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development, intellectual deficit or developmental delay
is common, and was reported in 18 out of 29 patients
examined [3]. Its severity is variable, and severe cases
have been reported, with neuro-motor deficit, microce-
phaly with simplified gyral pattern and epilepsy [7,11].
Intellectual deterioration is likely to be related in part to
secondary brain complications following diabetic coma
with ketoacidosis, severe hypoglycaemia, and recurrent
episodes of multi-organ failure. In addition, part of the
intellectual regression may occur through other
mechanisms which are specific to the disease process.
Central hypothyroidism has been reported in 6 out of
26 patients in the series of Ozbek et al. [12], who
observed that it was only reported during acute epi-
sodes, and proposed that central hypothyroidism is not
a component of the syndrome, but rather a reflection of
euthyroid sick syndrome occurring during severe epi-
sodes. Euthyroid sick syndrome is thought to be an
energy saving mechanism during stress conditions [13].
Neutropenia has been reported in some patients [6,9],
and is often associated with recurring infections. It was
reported in 8 out of 21 patients in the series of Ozbek
et al. [12]. Other clinical features have been reported in
only one or a small number of patients and may be
coincidental: discoloration of teeth and skin abnormal-
ities [1], and dysmorphic facies [5,9]. Additional clinical
features, including cardiac malformations and pulmon-
ary hypoplasia were also described in a patient diag-
nosed as WRS, and carrying a mosaic 15q11-12
deletion. However, this case was reported before the
genetic elucidation of the syndrome [14], and may cor-
respond to a genetically distinct disease.
Clinical variability
The clinical course of WRS is very variable, including
within the same sibship. Early age at onset of diabetes,
bone dysplasia and recurrent hepatic failures, which are
the most characteristic features, also show variability
between patients. Typically, onset of diabetes occurs
before age 6 months and bone dysplasia is diagnosed
Figure 2 Skeletal dysplasia and growth retardation in a WRS patient (age 13 years). A: Photograph of patient, showing disproportionately
short trunk and genu valgum. B: growth chart showing severe dwarfism with poor growth rate.
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before one or two years of age. Hepatic episodes may
occur at any time during the course of the disease, and
may be the first presenting manifestation after diabetes
onset. However, age at onset has been reported up to
2.5 years [2] and one patient was described with no
bone abnormalities at age 32 years [4]. The presence
and severity of other manifestations, i.e. renal failure,
exocrine pancreas deficiency, intellectual deficit,
hypothyroidism, neutropenia and recurrent infections,
are variable between patients. The variability in age at
onset, severity and nature of the clinical manifestations
and frequency of severe episodes of clinical manifesta-
tions explain the variable course of the disease between
patients, with survival ranging from a few weeks to 35
years. In some patients, some of the clinical manifesta-
tions may be missing due to the young age of the




WRS is a rare autosomal recessive disease. Genetic study
of two consanguineous families with a total of five
patients has established that the disease is caused by
mutations in the gene encoding eukaryotic translation
initiation factor 2a kinase 3 (EIF2AK3), also known as
pancreatic EIF2a kinase (PEK) and PKR-like endoplasmic
reticulum kinase (PERK) [15]. In accordance with the
general usage, we will denote the gene as EIF2AK3 and
the protein as PERK. PERK is a transmembrane protein
located in the endoplasmic reticulum (ER), which plays a
key role in the translation control during the unfolded
protein response (UPR). PERK, together with IRE1 and
ATF6, is a stress sensor in the ER, which detects the
accumulation of misfolded proteins and initiates
the appropriate cellular response of UPR that maintains
the cell integrity. Upon activation, it phosphorylates the
translation initiation factor eIF2a, which in turn reduces
protein synthesis, and it also activates the expression of
stress-related proteins, such as ATF4, which increases
the expression of other transcription factors such as
ATF3 and CHOP, that regulate a variety of cellular pro-
cesses, including amino acid metabolism, oxidative stress,
and apoptosis (figure 3). Both mechanisms contribute to
preventing overload of the secretory process (for reviews,
see [16] and [17]).
In subsequent studies, many mutations have been
reported in the EIF2AK3 gene in WRS patients [2-4].
These mutations are either nonsense or frameshift
mutations resulting in premature termination of the
protein, or missense mutations located in the kinase
domains of the protein (Figure 4). Overall, a total of 39
distinct mutations have been reported, 25 (64%) of
which are frameshift or nonsense mutations, 12 (31%)
missense and 2 (5%) splice mutations. In most families
(39/42) these mutations were homozygous, as a conse-
quence of consanguineous or endogamic marriages, and
in three cases they were compound heterozygous. To
date, all patients presenting “typical” clinical manifesta-
tions of WRS have been found to carry homozygous or
compound heterozygous mutations in EIF2AK3, respon-
sible for the disease. However, in a single patient born
from a consanguineous marriage presenting the associa-
tion of early onset insulin-dependent diabetes (age 18
months) and multiple epiphyseal dysplasia, EIF2AK3
mutations and involvement of this gene were excluded
[2]. In contrast to all other WRS patients, this patient
had none of the other clinical manifestations character-
istic of the disease, including episodes of hepatic failure,
and had a border-line level of GAD autoantibodies. This
may be a variant form of WRS, or it may be a fortuitous
association. In another family, a novel mutation in the
PTHR1 gene was found to be responsible for a form of
very rare epiphyseal dysplasia, Eiken syndrome [18], that
has been described only in this family [19]; one of the
four Eiken patients studied had Type 1 Diabetes (T1D),
with juvenile onset and the presence of GAD autoanti-
bodies, which is likely to represent a fortuitous associa-
tion. It should be noted that syndromic disease
presentations occurring in consanguineous families,
even in the case of rare diseases, may also reflect coinci-
dental associations.
Genetic contribution to clinical variability
Remarkably, patients and siblings who share the same
mutation in EIF2AK3 gene are frequently discordant for
their extra-endocrine pancreas manifestations, including
intellectual deficit, exocrine pancreas deficiency,
hypothyroidism, neutropenia and recurrent infections,
and the presence and frequency of episodes of liver fail-
ures [2,3]. Therefore the nature of the mutation is not
sufficient to explain most of the clinical variability of the
syndrome. Neutropenia may be an exception, as it was
consistently shared or not shared within patients carry-
ing the same mutation [3]. In particular, it was observed
in four out of four patients studied from two Turkish
families with the W522X mutation, three out of three
French/Tunisian siblings with the Fs346X346 mutation,
one child with a Fs910X956 in a single-affected family,
and none of the other reported cases [3]. This hypoth-
esis still remains unconfirmed at present, due to the
small number of observations, and the apparent absence
of any specificity in the nature of the mutation in these
cases. In addition, significantly older ages at onset have
been reported in two patients, at 30 months and 14
months [2,4]. In the first case, the mutation, N656K,
was shown to have a residual kinase activity in vitro,
which may explain the delayed onset in this patient [2].
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Although no activity test was performed for the muta-
tion of the second patient, it is notable that it is located
very near the first one, at I650T in the first kinase
domain, and we hypothesize that mutations with resi-
dual kinase activity may be associated with a delayed
age at onset of diabetes, although the rest of the pheno-
type appears typical of WRS. In addition, a single WRS
patient with no skeletal manifestations was reported,
who was alive at 32 years old [4]. This patient is homo-
zygous for a F593L mutation. The other patient who
survived longer (age 35) was homozygous for a L646P
mutation, also located in the first kinase domain. Hence,
mutations that have been associated with a relatively
milder phenotype (later onset or longer survival) appear
to all be missense mutations located in the first kinase
domain (Figure 4).
Pathophysiology
Mice deficient for Perk show a remarkably similar phe-
notype to human WRS, including permanent neonatal
diabetes, growth retardation and skeletal dysplasia, hepa-
tic dysfunction and exocrine pancreas deficiency [20,21].
These mice models have proven very useful to dissect
the pathophysiology of WRS. Detailed genetic studies of
tissue-specific and cell-specific knockouts showed that
diabetes is specifically caused by the loss of Perk expres-
sion in b cells [22], exocrine pancreas dysfunction by
the loss of Perk expression in acinar cells [23], and
Figure 3 Schematic representation of the main UPR mechanisms, focusing on PERK related pathways. Upon accumulation of misfolded
proteins in the ER lumen, chaperones such as BiP are displaced from the ER stress sensors PERK, IRE1 and ATF6, resulting in their activation.
Upon phospohorylation, PERK assembles in a homodimer (active form), which phosphorylates EIF2a, initiating the downstream UPR response,
that reduces the protein overload to the ER: 1) reduction of protein translation and 2) activation of ATF4 and other transcription factors
including ATF3 and CHOP, resulting in a variety of cellular and biological effects. ATF3 and CHOP are also involved in a regulatory feedback
control of PERK-EIF2a dependent on GADD34. PERK also regulates ATF6, which induces the expression of chaperones, such as BiP and ERp72,
which are essentiel in protein processing and quality control. Misfolded proteins are then dissociated by retrotranslocation to the cytosol and
degradation by the ubiquitine/proteasome complex (ER associated degradation, or ERAD).
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skeletal dysplasia and osteopenia by the loss of Perk
expression in osteoblasts [24]. These studies showed
that Perk is required for fetal and early neonatal devel-
opment of b cells and for b cell function [22]. As a con-
sequence, Perk knockout (KO) mice have severely
reduced b cell mass and insulin secretion, resulting in
neonatal diabetes.
In Perk KO mice, hypoglycemia precedes the onset of
diabetes, but is absent in pancreas-specific Perk KO
[22], suggesting the role of impaired neoglucogenesis
due to liver dysfunction. This is likely to contribute to
the recurrent hypoglycemia episodes in WRS patients.
Although hypoglycemia has not been reported in WRS
patients before diabetes onset, to our knowledge, we
cannot exclude that such episodes may be undiagnosed,
in the absence of other clinical manifestations prior to
diabetes onset, and may result in early death of these
patients before diagnosis, as observed in Perk KO mice
in some specific genetic background (D. Cavener, pers.
communication).
In addition, growth retardation in Perk KO mouse has
been associated with reduced liver IGF-1 expression
during the neonatal period, and could be partly cor-
rected by IGF-1 injections [25], again involving liver
dysfunction in this specific feature of WRS.
Initially, in view of the known role of PERK in the
UPR, it was proposed that PERK deficiency may result
in a defect of the actively secreting b cell to handle the
ER stress resulting from this high demand, leading to an
accumulation of misfolded proteins, that would become
toxic to the cell and lead to apoptosis, resulting in
diabetes, independently of an autoimmune process
[20,26]. This hypothesis received further support from
the study of other monogenic diabetes, where a role of
ER stress of the b cell may also be implicated, including
Wolfram syndrome (WFS), caused by mutations in the
ER Ca2+ channel gene WFS1 [27], and neonatal diabetes
caused by structural mutations in the insulin gene itself
[28]. A role for ER stress has also been proposed as one
of the key mechanisms leading to frequent forms of dia-
betes, including type 1 and type 2 diabetes [17,20,29], as
well as a wide range of other common diseases, includ-
ing neurodegenerative (Huntington’s disease, Alzhei-
mer’s disease), inflammatory, cardiac and metabolic
diseases [30,31].
Recently, however, this hypothesis has been ques-
tioned, following detailed studies of b cell development
in Perk KO mice performed by D. Cavener’s group [22],
which showed that these mice had severely impaired
b cell proliferation and differentiation during the critical
fetal and neonatal periods, resulting in low b cell mass;
in addition, these mice have defective proinsulin traffick-
ing, and abrogation of insulin secretion. Further detailed
studies performed in b cell lines and in Perk KO mice
showed that Perk ablation resulted in reduced cell pro-
liferation and insulin secretion [32]. However, both in
Perk deficient mice and cell lines, there was no evidence
of uncontrolled protein synthesis and of activation of
the ER stress specific pathway and cell death. Rather,
there was impaired ER to Golgi trafficking and defective
ER associated degradation (ERAD), suggesting that ER
dysfunction is responsible for the decreased cell
Figure 4 Schematic representation of PERK and all mutations reported to date. PERK is composed of a signal peptide (sp), followed by a
regulatory domain and a catalytic domain that contains two serine-threonine kinase domains (orange bars). PEK mutations that result in
missense mutations are all located within or in the near vicinity of kinase domains (orange blocks). Nonsense (X) and frameshift (FS) mutations,
that result in truncated proteins are represented below, and are spread over the length of the protein. Mutations that were found as compound
heterozygous in WRS patients are labelled with a “(c)”, all others were found in the homozygous state in WRS patients. Mutations homozygous
in patients with a relatively late diabetes onset (14 and 30 months) are noted by “(1)” and those homozygous in patients with a relatively longer
survival (32 and 35 years) are noted by “(2)”. Two mutations were splice mutations located in intron and are not represented. PERK sequence
and the position of mutations are provided relative to NCBI RefSeq (NP_004827).
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proliferation, abnormal insulin trafficking and insulin
secretion observed in b cells of KO mice and WRS
patients [32,33].
Histological features
Histological studies performed on the bone, pancreas
and liver of WRS subjects have shown very specific fea-
tures, that are valuable to our understanding of disease
mechanisms. In the first publications describing this
syndrome, a defect in ossification was well documented
on bone biopsy, with particular abnormalities of the car-
tilage in the form of hypertrophic chondrocytes
[1,34,35]. Further studies reported an irregular prolifera-
tion of chondrocytes in the resting cartilage, with the
presence of excessively thin ramified collagen fibers in
the spongy bone [9].
In the liver, biopsies performed outside of the recur-
rent episodes of liver dysfunction typically show pro-
gressive fibrosis with mild steatosis and intrahepatic
cholestasis [7]. Postmortem examination showed steato-
sis and lesions of massive necrosis, which is non-inflam-
matory and has a very remarkable aspect, where cells
are isolated or grouped in clusters juxtaposed to normal
hepatocytes, producing a mosaic appearance (Figure 5;
S. Collardeau-Frachon, pers. communication). Similar
necrotic lesions were also observed in the kidney (S.
Collardeau-Frachon, pers. communication).
The pancreas is typically hypoplastic with a reduction
of acinar tissue that exhibits evidence of necrosis, with
similar histological characteristics to the liver (Figure 6;
S. Collardeau-Frachon, pers. communication). Langer-
hans islets are smaller than normal, in relation with the
severe b cell defects, as evidenced by immunohisto-
chemical study showing a major reduction of insulin
staining, whereas the majority of cells stain for glucagon
(Figure 7) [36].
Overall, both in human WRS and Perk KO mice, the
necrotic lesions observed in the liver, kidney and exo-
crine pancreas appear histologically very similar, con-
trasting with the absence of similar features in the
endocrine pancreas and the bone. Indeed, in b cells and
osteoblasts, detailed mouse studies showed clear evi-
dence for proliferation and differentiation defects, rather
than cell death [22,24,33]. In view of the broad range of
mechanisms controlled by PERK, it is likely that the
variety of cellular consequences of PERK deficiency
observed in different organs and cell types reflect the
variety of the mechanisms and pathways that may be
affected, directly or indirectly. The consequences for b
cells, resulting in diabetes in WRS patients, appear to
affect principally the proliferation and differentiation of
the cells, as well as proinsulin trafficking and insulin
secretion [33]. Similar mechanisms acting on the highly
secreting osteoblasts are likely responsible for the bone
defect observed in WRS, as demonstrated in Perk KO
mice [24]. In contrast, the necrosis appearance observed
in the liver, kidney and exocrine pancreas suggests the
implication of distinct mechanisms, timing or regula-
tions, which may result in cell death in a cell-specific
manner. Detailed investigation of the exocrine pancreas
Figure 5 Liver histology. Hematoxylin phloxin saffron stain (× 400). Arrows show ballooning aspect of hepatocytes with steatosis (A) and
necrosis with accumulation of hyperacidophilic intracytoplasmic material (B). WRS: WRS patient, N: normal control. (histological study performed
by R. Bouvier and S. Collardeau-Frachon, Lyon).
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in exocrine-specific Perk KO mice showed that the
mode of cell death in this tissue is oncosis rather than
apoptosis, and there was no evidence of defective pro-
tein synthesis and secretion, a normal appearance of the
ER in these cells, and no evidence of ER stress, but a
strong inflammatory response [23]. Finally, recent stu-
dies in Perk KO mice suggest that PERK may act as a
metabolic sensor in the b cells, to modulate the traffick-
ing and quality control of proinsulin to the physiologic
demand in insulin [33]. This adaptive mechanism is
likely to play a central role in frequent forms of diabetes
and metabolic diseases. The remarkably similar clinical
and histological characteristics of human WRS and Perk
KO mice stress the value of detailed studies of global
and organ-specific Perk KO mice in order to dissect the




WRS should be suspected in any infant who presents
with permanent neonatal diabetes associated with skele-
tal dysplasia and/or episodes of acute liver failure. Since
part of the key presenting features of the syndrome may
occur later during the course of the disease, WRS
should be suspected in any infant with diabetes mellitus
occurring neonatally or at a very young age (before
6 months) originating from a population where there is
a high prevalence of consanguinity, or in case of history
of neonatal diabetes with rapidly fatal outcome in
siblings or in the extended family; these patients should
be assessed radiologically for early signs of skeletal
abnormalities and deficient mineralization. Growth
retardation and short stature in WRS patients can gen-
erally be documented clinically only after the age of one
year or so. From that age, gradual slowing of growth
rate is generally observed with growth retardation that
sometimes becomes extremely severe. Growth para-
meters are progressively below 5 SD for the age with
time (Figure 2B). For older patients, there is a tendency
for a permanent cessation of growth after the age of 10
years, in relation with the development of bone lesions.
It should be noted that the extent of the clinical varia-
bility of the syndrome may not be fully known at pre-
sent, as a consequence of its rarity, and age at onset,
bone dysplasia and liver failure should not be required
for suspecting WRS in a patient with early-onset dia-
betes. Homozygous EIF2AK3 mutations have been
found in WRS patients with age at onset up to 2.5 years
[2], in one WRS patient with no bone dysplasia at age
32 years [4], and hepatic failure has not been reported
in all WRS patients [3]. Although WRS is a rare syn-
drome, it now appears to be the most frequent form of
neonatal/early-onset permanent neonatal diabetes in
patients born from consanguineous parents, where it
may account for 25% of cases [4]. We suspect that WRS
is largely underdiagnosed at present because of the early
death of patients and/or the higher prevalence of these
patients in countries where structures for health care
may not be optimal.
Figure 6 Pancreatic histology. Hematoxylin phloxin saffron stain (× 400). Acinar structures are reduced in number and exocrine cells show
abundant cytoplasm and hyperacidophilic material in WRS patient. Langerhans islets are smaller in WRS than in normal control. WRS: WRS
patient, N: normal control. (histological study performed by R. Bouvier and S. Collardeau-Frachon, Lyon).
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Figure 7 Pancreatic histology (islets). Staining of Langerhans islets using immunoperoxydase with specific antibodies against insulin and
glucagon (× 400). A: WRS patient; B: Normal control. In WRS patient, the majority of the cells within the islets stain for glucagon. Numerous cells
also stain positively for somatostatin (not shown), and there is a marked reduction in the number of insulin-secreting b cells, which are sparse
within the islets. (histological study performed by R. Bouvier and S. Collardeau-Frachon, Lyon).
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Genetic diagnosis
In view of the relatively high prevalence of WRS syn-
drome evidenced by EIF2AK3 mutations in neonatal/
early onset diabetic patients born from consanguineous
parents, we recommend systematic sequencing of the
coding regions of EIF2AK3 gene in patients born from
consanguineous parents, or coming from isolated popu-
lations with frequent inbreeding, even in the absence of
any evidence of osteoporosis or bone abnormalities at
disease onset. This early diagnosis is important in order
to follow up these patients more carefully, and in parti-
cular to insure rapid care during episodes of hepatic
failure.
Differential diagnosis
WRS should be differentiated from other forms of neo-
natal or early-onset insulin-dependent diabetes, based
on the clinical presentation. Ultimately, EIF2AK3 muta-
tion screening confirms (or excludes) the WRS diagno-
sis. The hypothesis of a variant form of WRS, not
caused by EIF2AK3 mutation and with variant clinical
features, remains a possibility, but should be confirmed
in additional cases [2].
WRS is always permanent after disease onset, which
easily distinguishes it from transient neonatal diabetes,
which is caused by other genetic defects. Most cases of
PNDM occurring before the age of 6 months are
thought to be largely genetically distinct from typical
T1D, based on the absence of distortion of HLA class II
allele distribution compared to control individuals
[37,38]. In contrast to T1D, WRS patients do not have
b cell specific autoantibody at disease onset.
Other genetic causes of PNDM have been identified,
in which diabetes may be isolated (non-syndromic) or
syndromic. Non-syndromic diabetes can be caused by
dominant or recessive mutations in the potassium chan-
nel genes KCNJ11 and ABCC8, or the insulin gene
(INS), or by recessive mutations in glucokinase gene
(GCK); additional neuro-motor and neuro-psychological
abnormalities are frequently observed in patients with
KCNJ11 and ABCC8 mutations. In outbred Caucasian
populations, heterozygous mutations in KCNJ11, ABCC8
or INS genes may account for almost 40% of PNDM,
compared to less than 5% in consanguineous families; in
contrast homozygous mutations at INS, GCK or ABCC8
genes may account for a total of 30% and EIF2AK3
mutations for almost 25% of PNDM patients in consan-
guineous families [4]. Although WRS is easily distin-
guished from these other forms of PNDM based of the
additional clinical features, they may be mistaken at the
time of diabetes diagnosis, when the rest of the syn-
drome is not yet expressed. Careful inspection of early
signs of deficient bone mineralization and skeletal dys-
plasia should be searched for at the time of diagnosis.
Although the age at onset of diabetes and birth weight
may be additional distinctive features, in that patients
with EIF2AK3 and ABCC8 homozygous mutations tend
to have a later age at onset and slightly greater birth
weight than patients with homozygous mutations at
GCK and INS [4], this criteria may not be fully diagnos-
tic because of the overlap of distributions.
Other rare autosomal recessive forms of PNDM,
which are associated with various organ impairments,
have been genetically characterized and are easily differ-
entiated from WRS: PDX1 mutations cause pancreas
agenesis with additional exocrine pancreas deficiency
[39], or a variant form with only neonatal diabetes [40];
PTF1A mutations cause pancreas and cerebellar agenesis
[41]; GLIS3 mutations cause neonatal diabetes, congeni-
tal hypothyroidism and other clinical features [42].
FOXP3 mutations (X-linked) are responsible for neona-
tal diabetes syndrome associated with X-linked immune
dysregulation and enteropathy [43].
The short stature related to skeletal dysplasia, regard-
less of other dysfunctions that occur in patients with
WRS, may be evocative of other spondylo-epiphyseal
dysplasias such as mucopolysaccharidoses. Early-onset
T1D occurring in these patients may also lead to a simi-
lar phenotype as WRS. In such cases however, disease
onset is likely to be older, and b cell specific autoantibo-
dies should differentiate them from true WRS.
In summary, in view of the straightforward genetic
diagnosis, we recommend EIF2AK3 mutation screening
for diagnosis in all neonatal/early-onset diabetes patients
(at least before age of 6 months) with clinical features
specific for WRS, or in the absence of extra-pancreatic
manifestations in PNDM patients born from consangui-
neous parents.
Genetic counselling and antenatal diagnosis
Genetic counselling of WRS is strongly recommended.
As a rare autosomal recessive disease, with no clinical
manifestations in parents, genetic counselling can only
be proposed to parents of a previous diagnosed WRS
child, with confirmed EIF2AK3 mutation. Recurrence
risk is 25% in siblings of WRS patients. In cases of
extended consanguineous families with a genetically
diagnosed WRS case, other related consanguineous
couples should also benefit from genetic counselling,
and their carrier status for the EIF2AK3 mutation
determined.
In view of the early disease onset and severe condition
and prognosis of WRS at present, prenatal diagnosis is
strongly recommended for this disease. Pregnancies are
generally uncomplicated, and the only prenatal diagnosis
of WRS is genetic diagnosis, based on genotyping the
EIF2AK3 mutation(s) that is(are) present in both parents
(heterozygous carriers).
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Clinical management
In terms of diabetes, close therapeutic monitoring
should be recommended because of the tendency for
frequent acute episodes of both hypoglycaemia and
ketoacidosis. Under this context, treatment with insulin
pump is recommended, especially in small infants, in
order to optimize the prevention of severe hypoglycae-
mia. Generally, in contrast with patients affected with
other forms of diabetes, treatment with insulin should
not target a very tight control of blood glucose, in order
to avoid hypoglycemia, which may trigger episodes of
acute aggravation of the disease. In practice, children
with WRS have a risk of developing acute multi-organ
failure during intercurrent illness. It is very important to
inform the patient’s relatives in order that they can
recognize these episodes very early so that hospitaliza-
tion can be organized very rapidly and appropriate
symptomatic treatment instituted. Bone fractures may
be frequent and must be managed at the orthopaedic
level. In WRS patients, interventions under general
anaesthesia increase the risk of acute aggravation, as a
consequence of the toxicity of anaesthetics, and should
be avoided when possible. Similarly, any drug or vaccine
not strictly necessary should be limited, taking into
account the risk of triggering secondary liver and/or kid-
ney failure.
Prognosis
The prognosis is poor, and WRS patients generally die
at a young age. In a review of 19 patients with known
age at death, only 3 died at 10 years or older [3]. Two
patients were reported with a longer survival, until 35
years for one patient [2], and alive at 32 years old for
one patient [4]. In general, in the final episode of aggra-
vation, the patient is initially admitted to the hospital
with flu-like symptoms and fever. Death occurs later in
a situation of multi-organ failure with predominant liver
and renal dysfunction, hepatic failure being sometimes
associated with encephalopathy. Remarkably, acute liver
episodes had not been reported in the patient who sur-
vived until age 35 years.
Future prospects
In view of the observed ER dysfunction in WRS patients,
intervention strategies targeting a reduction of ER stress
or other pathways involved in this dysfunction are of
potential interest for therapy and possibly prevention.
Recent studies targeting ER stress reduction using che-
mical chaperones, glucagon-like peptide-1 (GLP-1) ago-
nists or other strategies have reported promising results
in vitro and in vivo (cellular and animal models), and in
particular regarding protection of b cells from ER stress
[31,44]. Wolfram syndrome (WFS), a monogenic
diabetes, is caused by mutations in the WFS1 gene,
another important ER gene. Interestingly, treatment of
Wfs1 KO mice with pioglitazone was found to reduce b
cell loss and protect mice from diabetes [45]. As ER
stress related mechanisms, or possibly other ER distur-
bance, have been suggested not only for monogenic dia-
betes such as WRS and WFS but also in frequent forms
of diabetes, such as T1D and T2D, and in other com-
mon conditions including obesity and cardiovascular
diseases, such intervention strategies may have very
large applications for health purpose.
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